GSK plc (NYSE:GSK) Shares Acquired by Manning & Napier Advisors LLC

Manning & Napier Advisors LLC raised its stake in GSK plc (NYSE:GSK - Free Report) by 33.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 200,000 shares of the pharmaceutical company's stock after acquiring an additional 50,000 shares during the quarter. Manning & Napier Advisors LLC's holdings in GSK were worth $6,764,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of GSK. Eastern Bank acquired a new position in shares of GSK in the 3rd quarter valued at $26,000. ST Germain D J Co. Inc. increased its holdings in GSK by 195.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company's stock valued at $27,000 after buying an additional 522 shares in the last quarter. Sunbelt Securities Inc. raised its position in shares of GSK by 73.8% in the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock worth $29,000 after acquiring an additional 302 shares during the period. Concord Wealth Partners boosted its stake in shares of GSK by 231.8% during the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company's stock worth $32,000 after acquiring an additional 547 shares in the last quarter. Finally, Fortitude Family Office LLC acquired a new stake in shares of GSK during the 3rd quarter valued at about $42,000. Hedge funds and other institutional investors own 15.74% of the company's stock.

GSK Price Performance

GSK traded up $0.32 on Thursday, hitting $35.38. 2,569,939 shares of the company's stock were exchanged, compared to its average volume of 3,993,111. The firm has a 50-day moving average price of $34.01 and a 200-day moving average price of $37.73. The stock has a market cap of $73.32 billion, a price-to-earnings ratio of 22.94, a P/E/G ratio of 1.31 and a beta of 0.63. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92.

Analyst Ratings Changes

GSK has been the topic of a number of recent analyst reports. Jefferies Financial Group downgraded GSK from a "buy" rating to a "hold" rating and lowered their price target for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Guggenheim lowered GSK from a "buy" rating to a "neutral" rating in a research report on Thursday, October 31st. StockNews.com lowered shares of GSK from a "strong-buy" rating to a "buy" rating in a report on Tuesday, January 21st. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a "buy" rating to a "hold" rating in a report on Friday, November 15th. Six research analysts have rated the stock with a hold rating, one has given a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.